The ALDH3A2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout cell population originating from the A-549 human lung adenocarcinoma epithelial cell line. This product comprises a heterogeneous pool of cells with targeted disruption of the ALDH3A2 gene, offering a versatile loss-of-function model for investigating aldehyde metabolism and oxidative stress biology. The polyclonal format reflects the inherent variation of gene-editing outcomes, making it well-suited for population-based functional studies without clonal selection.
The host A-549 cell line is a widely characterized model derived from a 58-year-old Caucasian male with lung adenocarcinoma. These adherent cells exhibit epithelial morphology and a hypotriploid karyotype, and they are extensively employed to study lung cancer biology, drug metabolism, and oncogenic signaling pathways. The robust and reproducible nature of A-549 cultures provides a reliable platform for genetic perturbation and subsequent phenotypic analyses.
ALDH3A2 encodes a fatty aldehyde dehydrogenase that catalyzes the oxidation of medium- and long-chain aliphatic aldehydes to their corresponding carboxylic acids, a critical detoxification step for aldehydes generated from lipid peroxidation. Transcription of ALDH3A2 is regulated by PPAR??, NRF2, and HIF-1??, linking its expression to metabolic and stress-responsive pathways. The enzyme modulates downstream levels of fatty acids, reactive oxygen species, and lipid aldehyde conjugates. It interacts with fatty aldehyde dehydrogenase (FALDH) and other ALDH family members, and it functionally cooperates with cytochrome P450 enzymes such as CYP4F2 and the aldo-keto reductase AKR1B10 in broader aldehyde and alcohol metabolism networks. Disruption of ALDH3A2 disrupts these interactions, potentially leading to accumulation of cytotoxic aldehydes and increased oxidative stress.
Within the A-549 lung adenocarcinoma background, loss of ALDH3A2 function provides a powerful system to examine the intersection of aldehyde metabolism and cancer cell physiology. Cancer cells often exist under heightened oxidative conditions, and impaired aldehyde clearance may exacerbate oxidative damage, influence cell viability, and modulate sensitivity to chemotherapeutic agents. This model is particularly valuable for exploring mechanisms of chemoresistance in non-small cell lung cancer, where ALDH3A2 may contribute to drug detoxification. Additionally, it serves as a cellular model for Sj?gren-Larsson syndrome, recapitulating metabolic defects caused by ALDH3A2 deficiency in a human cancer context.
Researchers can utilize these polyclonal knockout cells in diverse functional assays, including measurement of aldehyde dehydrogenase activity, ROS quantification with probes like DCFDA, lipid peroxidation assessment by TBARS, and cell viability, migration, and invasion studies. Drug sensitivity can be profiled through MTT or IC50 assays, and the model is amenable to screening ALDH3A2 inhibitors. Routine molecular characterization is supported by western blotting for protein levels and RT-qPCR for transcript analysis. For additional technical assistance, please contact Ascent Research.
